We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alnylam (ALNY) Reports Q3 Earnings: What Key Metrics Have to Say
Read MoreHide Full Article
Alnylam Pharmaceuticals (ALNY - Free Report) reported $500.92 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 33.3%. EPS of -$0.50 for the same period compares to $1.15 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $529.34 million, representing a surprise of -5.37%. The company has not delivered EPS surprise, with the consensus EPS estimate being -$0.50.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Alnylam performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net Product Revenue- Oxlumo- United States: $14.93 million compared to the $15.73 million average estimate based on two analysts. The reported number represents a change of +53.7% year over year.
Net Product Revenue- Amvuttra- United States: $168.66 million versus $153.83 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +48.6% change.
Net Product Revenue- Givlaari- United States: $40.37 million compared to the $42.96 million average estimate based on two analysts. The reported number represents a change of +9.1% year over year.
Net Product Revenue- Onpattro- United States: $16.21 million versus the two-analyst average estimate of $18.23 million. The reported number represents a year-over-year change of -25.9%.
Revenues- Product revenues, net: $420.15 million versus the 10-analyst average estimate of $414.11 million. The reported number represents a year-over-year change of +34.2%.
Revenues- Royalty revenue: $23.39 million versus $22.32 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +136.1% change.
Revenues- Net revenues from research collaborators: $57.39 million compared to the $96.03 million average estimate based on nine analysts.
Net Product Revenues- Oxlumo: $40.22 million versus $42.33 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +40% change.
Net Product Revenues- Givlaari: $71.04 million versus the seven-analyst average estimate of $65.53 million. The reported number represents a year-over-year change of +31.2%.
Net Product Revenues- Amvuttra: $258.59 million compared to the $240.23 million average estimate based on six analysts. The reported number represents a change of +73.9% year over year.
Net Product Revenues- Onpattro: $50.29 million versus $65.28 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -38.4% change.
Net revenues from research collaborators- Other: $0.21 million compared to the $10.37 million average estimate based on three analysts.
Shares of Alnylam have returned +3.7% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Alnylam (ALNY) Reports Q3 Earnings: What Key Metrics Have to Say
Alnylam Pharmaceuticals (ALNY - Free Report) reported $500.92 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 33.3%. EPS of -$0.50 for the same period compares to $1.15 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $529.34 million, representing a surprise of -5.37%. The company has not delivered EPS surprise, with the consensus EPS estimate being -$0.50.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Alnylam performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Product Revenue- Oxlumo- United States: $14.93 million compared to the $15.73 million average estimate based on two analysts. The reported number represents a change of +53.7% year over year.
- Net Product Revenue- Amvuttra- United States: $168.66 million versus $153.83 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +48.6% change.
- Net Product Revenue- Givlaari- United States: $40.37 million compared to the $42.96 million average estimate based on two analysts. The reported number represents a change of +9.1% year over year.
- Net Product Revenue- Onpattro- United States: $16.21 million versus the two-analyst average estimate of $18.23 million. The reported number represents a year-over-year change of -25.9%.
- Revenues- Product revenues, net: $420.15 million versus the 10-analyst average estimate of $414.11 million. The reported number represents a year-over-year change of +34.2%.
- Revenues- Royalty revenue: $23.39 million versus $22.32 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +136.1% change.
- Revenues- Net revenues from research collaborators: $57.39 million compared to the $96.03 million average estimate based on nine analysts.
- Net Product Revenues- Oxlumo: $40.22 million versus $42.33 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +40% change.
- Net Product Revenues- Givlaari: $71.04 million versus the seven-analyst average estimate of $65.53 million. The reported number represents a year-over-year change of +31.2%.
- Net Product Revenues- Amvuttra: $258.59 million compared to the $240.23 million average estimate based on six analysts. The reported number represents a change of +73.9% year over year.
- Net Product Revenues- Onpattro: $50.29 million versus $65.28 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -38.4% change.
- Net revenues from research collaborators- Other: $0.21 million compared to the $10.37 million average estimate based on three analysts.
View all Key Company Metrics for Alnylam here>>>Shares of Alnylam have returned +3.7% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.